An update from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.
On January 29, 2025, OKYO Pharma Limited provided a clinical update and interim results for the six months ended September 30, 2024. The company is advancing its Phase 2a trial of OK-101 for neuropathic corneal pain, with enrollment expected to be completed by the end of the second quarter of 2025. Additionally, OKYO reported positive results from its Phase 2b trial of OK-101 for dry eye disease, showing significant benefits in symptom improvement and a favorable safety profile. Financially, the company reported a reduced comprehensive loss compared to the previous year, reflecting an improvement in its financial standing. This progress positions OKYO to continue its engagement with the FDA for further clinical development.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The company is listed on the NASDAQ Capital Market and is dedicated to discovering and developing novel molecules for these ocular conditions.
YTD Price Performance: -8.32%
Average Trading Volume: 59,160
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.11M
See more data about OKYO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com